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1. Introduction
Coronary artery bypass grafting surgery (CABG) is one of the most effective therapies for
coronary artery disease (CAD). CABG is conventionally performed with the use of cardiopul‐
monary bypass (CPB), which has been associated with an increased frequency of complications
[1-3]. A variety of risk factors has been described to help delineate risk assessment of patients
undergoing CABG, including preoperative left ventricular ejection fraction (LVEF) [4, 5] and
postoperative increase in creatine kinase myocardial band (CK-MB) levels [6-11]. In patients
undergoing coronary artery bypass grafting (CABG), the use of cardiopulmonary bypass
(CPB) in combination with aortic clamping during coronary artery bypass grafting (CABG)
elicits ischemic myocardial injury [12]. The vascular endothelium is a complex synthetic organ
subject to injury from numerous potential insults, including oxidative stress [13, 14] modified
lipoproteins [15], and hemodynamic forces [16]. Injured endothelial cells initiate a largely
stereotyped, initially protective response. The concurrent uptake of low-density lipoproteins
(LDLs) by monocyte-derived macrophages transforms them in to the lipid laden foam cells
that constitute a key element of the fatty streak, the first recognizable progenitor of the
advanced atherosclerotic lesion [17, 18].
Silymarin, a flavonolignan from ‘milk thistle’ (Silybum marianum) plant, is used from ancient
times as a hepatoprotective, antioxidant, anti-lipid peroxidative, antifibrotic, anti-inflamma‐
tory, immunomodulatory and liver regenerating. Silymarin has cardioprotective activity
against ischemia-reperfusion induced myocardial infarction in rats [19].
Protective efficacy of Silymarin treatment confirmed by anti-inflammatory and antioxidant
actions against reperfusion injury and inflammation during CABG surgery [20].
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This may represent a novel cardioprotective agent to be used pre CABG, to our knowledge;
this is the first study of pretreatment Silymarin as cardioprotective agent in patients under‐
going CABG.
2. Patients and methods
The local ethics committee approved the investigation, and informed written consent was
obtained from all patients entering the study. 140 patients admitted to the hospital for the first
time for elective coronary artery bypass surgery were invited to take part. They were random‐
ized into three groups (G); G I: Administered Silymarin (Legalon® tablet), 140 mg×3; 1 day
before surgery. G II: Administered Silymarin (Legalon® tablet), 140 mg×3; 3 days before
surgery. G III: Control (no treatment). Patients receiving corticosteroids were deemed not
eligible. Any drugs were withheld on the morning of surgery.
Surgical procedure: Specifications on the extracorporeal circulation circuit, cardiopulmonary
bypass procedures and surgical procedures have been described previously [20].
At baseline, demographic data (age, sex, weight, BSA, BMI), and history of conventional
vascular risk factors (hypertension, diabetes mellitus, hyperlipidemia, smoking habit, alcohol
abuse) were obtained.
Routine laboratory investigations were performed the first day after admission to the hospital
after overnight fasting and later before discharged. It included levels of WBCs; differential
counts (Neutrophils, Monocytes, Lymphocytes), RBCs, ESR, total cholesterol, LDL, vLDL,
HDL, triglycerides, SGOT, SGPT, B.urea, S.creatinin, alkaline phosphatase, serum bilirubin,
blood sugar, HbA1c, & ESR. Blood samples for troponin I (T), & creatine kinase; (CK-MB)
measurement were obtained within 24 hours before surgery, & 2 hr, 24 hr post CABG. All
laboratory tests were performed according to companys' procedures. Laboratory staffs were
blind to the tested drug and groups.
Statistical analysis
The present Data was analyzed using Student ‘t’ test, one-way analysis of covariance. P< 0.05
was considered to be significant. All data were analyzed using the statistical package SPSS
(version 10.0) Continuous data are presented as mean ± SD and categorical data as absolute
numbers, or mean.
3. Results
One hundred and forty patients [105 (75%) males, and 35 (25%) females] with a mean age of
64.5 years were included in the study. All underwent on-pump CABG.
No significant differences were noted between the groups in age, body surface area, BMI, and
operation data. The demographic data on the 140 patients completing the study are presented
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in Table 1. Clinical & operative characteristics (Age, sex, body weight, smoking, left ventricular
ejection fraction, usual administered drugs, other diseases, family history of coronary artery






G IIIG I (n=40) G II (n=50)
Male/Female (No.) 68/22 37/13
Age (years) a 65 64
Body surface area (m2) b 1.6 ± 0.2 1.7 ± 0.1
BMI (kg/m2) b 42.3 ± 0.2 44.7 ± 0.2
Ejection fraction (%) b 58 ± 1 60 ± 1
Operative time (min) b 201 ± 16 200 ± 18
No. of grafts a 3 3.5
Hospitalization (days) a 4 7
Table 1. Clinical and Patients’ data in Silymarin treated and control groups.
There was a significant decrease in post operative values of; WBCs counts, Neutrophil, mono‐
cytes, lymphocytes, RBCs, ESR (Figure1), total cholesterol, LDL, vLDL, & triglycerides (Figure 2),
SGOT, SGPT, alkaline phosphatase (47%), showed in (Figure 3), B.urea, S.creatinine, serum
bilirubin (48%) (Figure 4), blood sugar, HbA1c in diabetic patients (43%) as showed in figure 5, in
SM treated group compared to baseline and control group; (P=0.002), while there was an elevation
of postoperative HDL values in patients treated with SM compared to control, (p=0.001).
Figure 1. The mean values of Neutrophils, Monocytes, Lymphocytes, total WBCs, RBCs, and ESR for Silymarin treated
and control groups pre and post CABG.
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Figure 2. The mean values (mg/dL) of total cholesterol, LDL, vLDL, HDL, and triglycerides for Silymarin treated and
control groups pre and post CABG.
Figure 3. Mean values of SGOT, SGPT, & Alkaline phosphatase for both groups compared pre and post CABG.
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Figure 4. The mean values of blood urea & serum creatinin, & serum bilirubin in tested groups pre & post operation.
Figure 5. Mean values of fasting blood sugar, & glycosylated heamoglobin pre & post CABG for both groups.
Surgery was associated with a significant increase in troponin I (T1), CK-MB (CK1) in both
groups, but after 24 hr post CABG there was a significant reduction of Troponin I (T2) values
in SM treated group compared to baseline (T0), after 2 hour (T1), and control group, [p=0.001].
SM-treated patients released significantly less creatine kinase (CK)-MB than the control
subjects postoperatively (CK1) after 2 hours, then back to normal levels after 24 hours (CK 2)
[p = 0.004]; indicating less myocardial injury in patients receiving SM when compared to the
control subjects (no significant change p > 0.05), as showed in figure 6.



















Figure 6. Mean Troponin I, & CK-MB values at different times in Silymarin (SM) treated patients and control groups.
[T0=pre CABG, T1=2 hours after CABG, T2= 24 hours after CABG, CK-MB 0=pre CABG, CK-MB 1= 2 hours after CABG,
CK-MB 2= 24 hours after CABG].
Patients treated with Silymarin before 3 days better than those treated before 1 day, but there
was no statistical significant differences between them (G I & G II), p>0.05.
4. Discussion
Myocardial ischemia and reperfusion is a common occurrence in CABG patients. Reintroduc‐
tion of oxygen to previously ischemic myocardium can result in irreversible tissue injury, and
Ischemic myocardial damage is associated with inflammation [21, 22].
SM has been shown to have a potential positive effect on immune function by its ability to
enhance neutrophil activity [23]. Silymarin & Silibinin by interacting with the lipid component
of cell membranes can influence their chemical & physical properties. Studies in erythrocytes,
mast cells, leucocytes, macrophages & hepatocytes have shown that SM renders cell mem‐
branes more resistant to lesions [24].
Studies have shown that silymarin exerts a number of effects, including inhibition of neutro‐
phil migration [25, 24]. The inhibitory effects of silymarin on neutrophil function prevent post
_ ischemic mucosal injury [26]. Activated neutrophils are thought to play a major role in
ischemia-reperfusion injury [27]. This study agrees with that, SM treated groups showed a
significant reduction of WBCs, neutrophils count post CABG, & ESR also. According to this,
silymarin may prevent reperfusion injury so it may have a beneficial effect during CABG.
Milk thistle was able to inhibit the biosynthesis of cholesterol in the liver and reduce LDL
cholesterol oxidation, one of the primary mechanisms of atherosclerosis [28,25]. This study
agrees with it, SM treatment showed a significant reduction of total cholesterol, LDL, & vLDL,
while HDL was elevated significantly.
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SM interact directly with the cell membrane components to prevent any abnormalities in the
content of lipid fraction responsible for maintaining normal fluidity [29].
Silymarin appears to act as an antioxidant not only because it acts as a scavenger of the free
radicals that induce lipid peroxidation, but also because it influences enzyme systems
associated with glutathione & superoxide dismutase [30]. Also, prevent damage to rat heart
membrane primarily through a free radical scavenging mechanism [31]. This study agrees with
previous mentioned studies, the antioxidant activity of Silymarin prevents vascular endothe‐
lium injury during CABG.
In the present study, all patients showed significantly higher plasma levels of markers of peri-
operative myocardial tissue injury early after the start of reperfusion. Silymarin treated group
showed a significant reduction of all measured parameters compared to baseline and control.
Alkaline phosphatase, & serum bilirubin was elevated preoperatively in 47%, and 48% of
enrolled patients, respectively, pretreatment with Silymarin showed a significant reduction
post operatively because SM have the ability to prevent injury from different causes.
Blood sugar & HbA1c in diabetic patients (43%) were diminished significantly in those treated
by SM.
SM counteracted the increase in the cardiac enzymes and cTnI concentration induced by
cisplatin, toward near normal levels. Rao and Viswanath 2007 [19] reported that the adminis‐
tration of SM before ischemia–reperfusion-induced myocardial infarction maintained the
levels of marker enzymes (LDH, CK and CK-MB) compared to isoproterenol-injected rats. A
possible explanation is that silymarin, via its anti-lipid peroxidation activity, causes stabiliza‐
tion of cardiac membranes and prevents the leakage of cardiac enzymes [32]. Silibinin induced
cardiac myocyte expression of Bcl-2 protein, which prevented permeability transition pore
opening, and, therefore, cytochrome c release decreased. These events might be one of the
mechanisms of silymarin-mediated stabilization of the mitochondrial membrane [33]. This
study agrees with the above study in which Troponin I, and CK-MB diminished significantly
in SM treated group compared to baseline and control.
The anti-inflammatory activity (significant reduction of cytokines post operatively), & antioxi‐
dant effects of SM during CABG [20], in addition to that, the highly significant reduction in serum
levels of troponin I, & CK-MB, confirm the cardioprotection activity of SM during CABG. This
mechanism of action may reduce ischemia-reperfusion injury, and protect the myocardium.
The results of this study indicate that SM pretreatment induces potent endogenous protection
against subsequent ischemic stress in the human myocardium, and reduced the damage
caused by reperfusion injury. SM has the ability to regulate membrane permeability and to
increase membrane stability in the presence of xenobiotic damage, capacity to regulate nuclear
expression by means of a steroid-like effect.
There was no statistically significant difference between the two treated groups, even the results
of patients treated with SM before 3 days better than those treated before 1 day of CABG sur‐
gery. The data of this study needs further large-scale, randomized, double blind technique studies
for other cardiovascular diseases to confirm the present study before clinical use of Silymarin.




The authors conclude that CABG surgery need using cardioprotective agent pre operation and
suggest using other pharmaceutical preparation I.V. dosage form of SM and studying the
pharmacokinetics during CABG surgery. The pre-operative administration of Silymarin may
reduce perioperative morbidity and myocardial injury during CABG surgery. The authors
suggest a large-scale, randomized, double blind study with cardiovascular events before
Silymarin could be considered for clinical use.
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